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In vascular smooth muscle cells, exposed to hyperglycemia
and insulin-like growth factor-I (IGF-I), SHPS-1 functions as a
scaffold protein, and a signaling complex is assembled that leads
to AKT activation. However, the underlying mechanism by
which formation of this complex activates the kinase that phos-
phorylates AKT (Thr308) is unknown. Therefore, we investi-
gated the mechanism of PDK1 recruitment to the SHPS-1 sig-
naling complex and the consequences of disrupting PDK1
recruitment for downstream signaling. Our results show that
following IGF-I stimulation, PDK1 is recruited to SHPS-1, and
its recruitment is mediated by Grb2, which associates with
SHPS-1 via its interaction with Pyk2, a component of the SHPS-
1-associated complex. A proline-rich sequence in PDK1 bound
to an Src homology 3 domain in Grb2 in response to IGF-I. Dis-
ruption of Grb2-PDK1 by expression of either a Grb2 Src
homology 3 domain or a PDK1 proline to alaninemutant inhib-
ited PDK1 recruitment to SHPS-1, leading to impaired IGF-I-
stimulated AKT Thr308 phosphorylation. Following its recruit-
ment to SHPS-1, PDK1 was further activated via Tyr373/376
phosphorylation, and this was required for a maximal increase
in PDK1 kinase activity and AKT-mediated FOXO3a Thr32
phosphorylation. PDK1 recruitment was also required for
IGF-I to prevent apoptosis that occurred in response to hyper-
glycemia. Assembly of the Grb2-PDK1 complex on SHPS-1 was
specific for IGF-I signaling because inhibiting PDK1 recruit-
ment to SHPS-1 had no effect on EGF-stimulated AKT Thr308
phosphorylation. These findings reveal a novel mechanism for
recruitment of PDK1 to the SHPS-1 signaling complex, which is
required for IGF-I-stimulatedAKTThr308 phosphorylation and
inhibition of apoptosis.
AKT is phosphorylated at two key regulatory sites, Thr308
in the activation loop of the catalytic domain and Ser473 in
the COOH-terminal domain. PDK1 (3-phosphoinositide-
dependent kinase 1) is the kinase responsible for phosphor-
ylation of Thr308 (1), and this is required for AKT-mediated
inhibition of apoptosis (2–5). Although constitutive auto-
phosphorylation of PDK1 Ser241 is required for PDK1 kinase
activity, it is not regulated by growth factors (1, 6). However,
PDK1 activity is regulated by changes in its conformation,
tyrosine phosphorylation, and subcellular localization (7–12).
PDK1 undergoes tyrosine phosphorylation in response to insu-
lin, angiotensin II, high glucose, and insulin-like growth factor-I
(IGF-I)2 (9, 11–17). Previous studies indicate that optimal acti-
vation of PDK1 requires phosphorylation of Tyr373/376 (11, 12,
14, 17), and growth factor receptor activation leads to PDK1
recruitment to the plasma membrane, followed by sequential
phosphorylation of Tyr9 and then Tyr373/376 (14, 17).
A previous study suggested that Pyk2 (proline-rich tyro-
sine kinase 2) plays an important role in PDK1 activation.
Tanniyama et al. (9) showed that Pyk2 was required for opti-
mal PDK1 tyrosine phosphorylation in response to angioten-
sin II and that Pyk2 and PDK1 were co-localized to the focal
adhesions. Pyk2 facilitates PDK1 interaction with Src, and
Tyr373/376 phosphorylation is increased in response to Src
activation (9, 12, 14, 18), but the mechanism by which these
signaling components interact, the involvement of other sig-
naling components, the exact sites of protein/protein inter-
action, and the mechanism of PDK1 membrane recruitment
leading to AKT Thr308 phosphorylation have not been
determined.
IGF-I has diverse biological actions, including regulation
of cellular proliferation, differentiation, migration, and
survival (19). The biological effects of IGF-I are mediated
through its receptor tyrosine kinase, which phosphorylates
specific substrates to activate downstream signaling (20, 21).
SHPS-1 (SH2 domain-containing protein tyrosine phospha-
tase substrate 1) is an integral membrane protein that acts as
a scaffold for multiprotein signaling complexes that are
assembled in response to IGF-I in vascular smooth muscle
cells or endothelial cells in response to hyperglycemia. The
SHPS-1 cytoplasmic domain (SHPS-1/CD) contains four
tyrosines that are phosphorylated by the IGF-I receptor (22).
This leads to recruitment of the SH2 domain containing
phosphatase SHP2. Subsequently, c-Src, p52Shc/Grb2 (growth
factor receptor-bound 2), and the p85 subunit of PI3K are
recruited and activated, leading to stimulation of both the PI3K
and mitogen-activated protein kinase (MAPK) signaling path-
ways (23–25). Truncation of the cytoplasmic domain (CD) of
SHPS-1 significantly impairs IGF-I-stimulated AKT activation
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(26). Recently, we reported that IGF-I stimulates Pyk2 recruit-
ment to the SHPS-1 signaling complex via Src-Pyk2 association
and that Src phosphorylates Pyk2Tyr881, creating a binding site
for Grb2 (27). Because, following hyperglycemic stress, IGF-I-
stimulated SHPS-1 phosphorylation results in a significant
increase in AKT phosphorylation, we wished to study whether
PDK1 is recruited to SHPS-1 signaling complex and, if so, to
determine the role of Grb2 in PDK1 recruitment in response to
IGF-I. Our findings demonstrate that Grb2 mediates the
recruitment of PDK1 to the SHPS-1 signaling complex, that
these signaling components interact through an SH3 domain-
polyproline motif interaction, and that PDK1 recruitment is
required for AKT Thr308 phosphorylation and cell survival in
response to IGF-I.
EXPERIMENTAL PROCEDURES
Human IGF-I was a gift from Genentech (South San Fran-
cisco, CA). Dulbecco’s modified Eagle’s medium (DMEM) con-
taining 4,500 mg of glucose/liter (25 mM) was purchased from
Invitrogen, and penicillin and streptomycin were purchased
from Invitrogen. Blasticidin was obtained from Invitrogen.
Phosphatidylinositol substrate was purchased from Avanti
Polar Lipids (Alabaster, AL). [-32P]ATP was from GE Health-
care. Antibodies against phospho-AKT (Ser473), phospho-AKT
(Thr308), AKT, PDK1, cleaved caspase-3, -actin, and HAwere
from Cell Signaling Technologies (Danvers, MA). An antibody
that detected pPDK1 (Tyr373/376) was from Abcam (Cam-
bridge, MA). The anti-Grb2 (rabbit), anti-p27 (rabbit), and the
monoclonal anti-phosphotyrosine antibodies (Tyr(P)99) were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). The Grb2, caveolin, and Pyk2 monoclonal antibodies
(mouse) were purchased from BD Biosciences. The anti-Pyk2
(rabbit) and anti-p85 subunit antibodies were purchased from
Upstate Cell Signaling Solutions/Millipore (Lake Placid, NY).
The anti-Src antibody was purchased from Calbiochem. A
polyclonal antibody for the extracellular domain of SHPS-1
was generated in our laboratory (26). The PI3K inhibitor
(LY294002) was purchased from Calbiochem. The DeadEnd
TUNEL kit was purchased from Promega (Madison, WI). All
other reagents were purchased from Sigma unless otherwise
stated.
Cell Culture—Vascular smooth muscle cells were prepared
from porcine aortas and maintained in culture as described
previously (28). All experiments except those shown in Fig. 6 (C
and D) were conducted in hyperglycemic conditions (25 mM
glucose). For the experiments in Fig. 6 (C andD), the cells were
grown in 10% FBS and DMEM containing 5 mM glucose and
then starved overnight in serum-freeDMEMcontaining 25mM
glucose before the treatments were added.
pLenti-HA-SHPS-1/Wild Type (SHPS-1/WT) and pLenti-HA-
SHPS-1/CD (MT-CD)—The full-length SHPS-1/WT and the
truncated cytoplasmic domain of SHPS-1 mutant (deleting
amino acids from 399 to 503) were PCR-amplified with HA-
containing primers using previously generated pcDNA-SHPS-1
as a template (23). That the construct contained the correct
sequence was confirmed by DNA sequencing, and then the
cDNAs were cloned into pLenti viral transduction system as
described previously (23, 26).
pLenti-HA-Grb2 Wild Type (Grb2/WT), pLenti-HA-Grb2
mutant (Grb2/WA), pLenti-HA-Pyk2 wild type (Pyk2/WT), and
pLenti-HA-Pyk2/Y881F (Pyk2/Y881F)—Grb2/WT, Grb2/WA,
Pyk2/WT, and Pyk2/Y881F were prepared as described previ-
ously (25, 27).
Generation of pLenti Expression Vectors pLenti-HA-PDK1
Wild Type (PDK1/WT) and pLenti-HA-PDK1 Mutant
(PDK1/PA)—The full-length PDK1/WT cDNA was prepared
by PCR using a pcDNA-myc-PDK1/WT construct kindly pro-
vided by Dr. Brian Hemmings (Friedrich Miescher Institute,
Basel, Switzerland) and cloned into the pENTR/D-TOPO
Gateway entry vector according to the manufacturer’s instruc-
tions (Invitrogen). The forward and reverse primers used to
generate the PCR product were as follows: forward primer,
5-CACC ATG ATG GCC AGG ACC ACC AGC CAG CTG-
3; reverse primer, 5-TTA AGC GTA ATC TGG AAC ATC
GTA TGG GTA TTA CTG CAC AGC GGC GTC CGG G-3.
The forward primer includes an ATG (underlined) start site.
The reverse primer contained the sequence encoding HA
epitope (underlined) followed by the stop codon (boldface
type).
Using the pENTR-PDK1/WT as template, the prolines at
positions 71 and 74 were charged to alanine (PDK1/PA) using
double-stranded mutagenesis. PCR amplification was carried
out using forward primer 5- gcatgcccagcctGcgccgcagGctcg-
gaagaagcggc-3 and reverse primer 5-gccgcttcttccgagCctgcg-
gcgCaggctgggcatgc-3, where capitalized bases indicate the
substitutions. After selection of correct clones as determined by
sequencing, the cDNAs encoding thewild type andmutant pro-
teins were transferred from the entry vector into pLenti6/V5-
DEST Gateway vector using the LR Clonase reaction following
the manufacturer’s instructions (Invitrogen).
Construction of a Plasmid Containing Short Hairpin RNA
(shRNA) Template for Pyk2 Silencing—The construction of the
plasmid containing shRNA template for Pyk2 was prepared as
described previously (27). The expression vector of shRNA
template for LacZ was used as a control. After confirmation of
the sequences, the plasmid DNAs were prepared and purified
using the Plasmid Midi kit (Promega, Madison, WI) according
to the manufacturer’s instructions.
Generation of Virus Stocks and Establishment of SMCs
Expressing pLenti Constructs—293FT cells (Invitrogen) were
utilized for generation of virus stocks that were prepared, puri-
fied, and transfected into vascular smooth muscle cells to
obtain cells expressing SHPS-1/WT, SHPS-1/CD, Pyk2/WT,
Pyk2/Y881F, Grb2/WT, Grb2/WA, PDK1/WT, PDK1/PA, si-
Pyk2, and si-LacZ. These cell lines were established using pro-
cedures that have been described previously (23, 25, 27). The
expression of the HA-tagged SHPS-1/WT, SHPS-1/CD,
Pyk2/WT, Pyk2/Y881F, Grb2/WT, Grb2/WA, PDK1/WT, or
PDK1/PA protein was detected by immunoblotting with an
anti-HA antibody (1:1,000); The effectiveness of shRNA for
inhibiting Pyk2 expression was determined by immunoblotting
using an anti-Pyk2 antibody and comparing the results to SMCs
expressing the LacZ shRNA. The immune complexes were
detected using either a horseradish peroxidase-conjugated
anti-rabbit or anti-mouse secondary antibody and developed
Role of PDK1 Recruitment to SHPS-1
SEPTEMBER 17, 2010 • VOLUME 285 • NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 29417
with enhanced chemiluminescence following the manufactur-
er’s instructions (Pierce).
Immunoprecipitation and Immunoblotting—The immuno-
precipitation and immunoblotting procedures were performed
as described previously (26).
In Vitro Binding Assay—The in vitro [35S]methionine (MP
Biomedicals, Solon, OH)-labeled PDK1/WT and PDK1/PA
mutant were generated by a coupled in vitro transcription and
translation (TNT) system (Promega) according to themanufac-
turer’s instructions. For the in vitro binding assay using agarose
bead-conjugated Grb2 protein (Santa Cruz Biotechnology,
Inc.), a 10-l aliquot of the individual TNT mixture was incu-
bated with 5 g of Grb2 beads in binding buffer (10 mMHepes,
pH 7.4, 150 mM NaCl, 0.1% Tween 20, 1 mM dithiothreitol) for
4 h at 4 °C. The beads were then washed three times with bind-
ing buffer. The precipitated proteinswere eluted in 30l of SDS
sample buffer, boiled for 5 min, and subjected to SDS-poly-
acrylamide gel. The images were developed and analyzed using
a Storm860 PhosphorImager (Amersham Biosciences).
Isolation Cytoplasmic and Membrane Fraction Proteins—
Isolation of cytoplasmic and membrane fraction proteins was
performed as described previously (29).
PI3K Assay—The immunoprecipitates containing the p85-
p110 complex were washed once with phosphate-buffered
saline, twice with lysis buffer, and once with the reaction buffer
(30) and resuspended in 50 l of the PI3K reaction buffer con-
taining 0.1 mg/ml phosphoinositide (Avanti Polar Lipids). The
reactions were performed, and the phosphorylated lipids were
separated by TLC as described previously (25, 31).
In Vitro Kinase Assay for PDK1—In vitro PDK1 activity was
measured as described previously (14, 16). In brief, cells were
incubated in serum-free medium overnight and then exposed
to 0 or 50 ng/ml IGF-I for 5 min. The cells were lysed in radio-
immune precipitation buffer, and the PDK1-containing im-
mune complexes were prepared by immunoprecipitating 0.5
mg of total proteinwith a 1:250 dilution of anti-PDK1 antibody.
The immune complexes were washed once with lysis buffer
containing 500 mM NaCl, followed by lysis buffer and finally
with kinase assay buffer (50 mM Tris-HCl, pH 7.5, 0.1% (v/v)
2-mercaptoethanol). In vitro kinase assays were performed for
45 min at 30 °C in 50 l of kinase assay buffer containing 30 l
of immunoprecipitate, 0.1 mM Suntide (RRKDGATMKTF-
CGTPE) as substrate, 10 mM MgCl2, 1 M protein kinase A
inhibitor peptide (Millipore), and 10 Ci of [-32P] ATP. Reac-
tions were stopped by adding EDTA to a final concentration of
50 mM. The amount of 32P that was incorporated into the sub-
strate peptide, which reflects the activity of PDK1 kinase, was
quantified by liquid scintillation counting (Packard, Meriden,
CT).
TUNEL Assay—Apoptosis was determined by a TUNEL
assay using the DeadEnd fluorometric TUNEL system accord-
ing to the manufacturer’s instructions (Promega, Madison,
WI). SMCs were washed once with PBS and then fixed with 4%
paraformaldehyde solution in PBS (pH 7.4) for 25 min at 4 °C.
Samples were permeabilized with 0.2% Triton X-100 solution
in PBS for 5min and then incubatedwith recombinant terminal
deoxynucleotidyltransferase for 1 h at 37 °C in a humidified
chamber. The slides were mounted in VECTASHIELD with
DAPI (Vector Laboratories, catalog no. H-1200) to stain nuclei
and detect localized green fluorescence of apoptotic cells on a
blue background using fluorescence microscopy. The number
of apoptotic cells in each sample was quantified by counting the
number of TUNEL-positive cells in three randomly selected,
non-overlapping regions. Each treatment was analyzed in trip-
licate. The results represent mean values of three independent
experiments.
Statistical Analysis—Student’s t test was used to compare
differences between treatments. The results that are shown in
all experiments are the representative of at least three inde-
pendent experiments and expressed as the mean  S.E.
RESULTS
IGF-I Stimulates PDK1 Recruitment to SHPS-1 and Loss of
PDK1 Recruitment Attenuates AKT Thr308 Phosphorylation—
Because PDK1 is a kinase that phosphorylates AKT on Thr308
and its membrane localization is essential for PDK1 activation
(1, 32), we determined whether PDK1 recruitment to SHPS-1
was stimulated by IGF-I. Untransfected SMCs exposed to
hyperglycemia and IGF-I showed a 4.6 1.1 (mean S.E.)-fold
increase in PDK1-SHPS-1 association (Fig. 1A). In addition,
IGF-I stimulated a 2.1 0.5-fold increase in PDK1 recruitment
to the membrane fraction in untransfected cells (supple-
mental Fig. 1). In contrast, cells expressing a truncated form of
FIGURE 1. PDK1 is recruited to SHPS-1 in response to IGF-I, resulting in
enhanced AKT phosphorylation. A, nontransfected, confluent SMC cultures
were serum-starved overnight and then stimulated with IGF-I (50 ng/ml). The
cells were lysed, and immunoprecipitation was performed using an anti-
PDK1 antibody, followed by immunoblotting with anti-SHPS-1. To control for
loading, the blot was stripped and reprobed with anti-PDK1. B, cells that were
expressing HA-tagged SHPS-1/WT or HA-tagged MT-CD were serum-starved
and stimulated with IGF-I. Lysates were immunoprecipitated (IP) with anti-
HA, followed by immunoblotting with an anti-PDK1. The blot was stripped
and reprobed with anti-HA as a loading control. C, membrane proteins were
isolated as described under “Experimental Procedures” and immunoblotted
with anti-PDK1. The blots were stripped and reprobed with anti-caveolin as a
membrane fraction marker and anti-14-3-3 as a cytoplasmic fraction marker.
D, both SHPS-1 WT and MT-CD cells were exposed to IGF-I, and cell lysates
were analyzed by direct immunoblotting for phospho-AKT (Thr308). The blot
was stripped and reprobed with anti-AKT as a loading control. The protein
levels were quantified using scanning densitometry. The graph shows the
mean result from three independent experiments expressed as relative phos-
pho-AKT/AKT ratio, which was calculated using arbitrary scanning units (D,
bottom). **, p  0.01 indicates the significant difference between the two cell
types. Error bars represent S.E.
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SHPS-1 in which the cytoplasmic domain was deleted (SHPS-
1/CD; MT-CD) showed no detectable PDK1-SHPS-1 associ-
ation after IGF-I treatment (Fig. 1B). The levels of HA were
confirmed to be the same when SHPS-1/WT- and MT-CD-
expressing cells were compared (supplemental Fig. 2A). Fur-
ther, analysis of the PDK1 content in the membrane fraction
showed that it was significantly reduced in cells expressing
MT-CD, suggesting that SHPS-1 association was required for
its recruitment to the membrane fraction (Fig. 1C). Following
IGF-I stimulation, there was a significant reduction (74.5 
10.1%, n  3, p  0.01) in AKT Thr308 phosphorylation in cells
that expressed MT-CD compared with cells expressing SHPS-
1/WT (Fig. 1D). Because deletion of the SHPS-1/CD would be
predicted to alter the activation of multiple signaling elements,
wewished to establish amethod for selectively inhibiting PDK1
association with the SHPS-1 signaling complex. Therefore, we
conducted studies to determine the mechanism of PDK1
recruitment to SHPS-1.
Grb2 Mediates PDK1 Recruitment to SHPS-1—PDK1 does
not contain SH2 domains and does not bind directly to phos-
pho-SHPS-1. Therefore, we searched the PDK1 sequence for
motifs that might bind to known SHPS-1 binding partners.
PDK1 does contain a polyprolinemotif that has the potential to
bind to the SH3 domain in Grb2, a component of the SHPS-1
complex. Following IGF-I stimulation, PDK1-Grb2 association
was increased 5.4  1.2-fold (p  0.01) (Fig. 2A). To determine
if this was mediated through the Grb2 SH3 domain, we utilized
a mutant in which both SH3 domains in Grb2 were altered by
substituting tryptophans at positions 36 and 193 with alanine
(Grb2/WA). These substitutions had been shown to alter Grb2
SH3 domain-polyproline motif interactions (25, 33). Grb2
binding to PDK1 was significantly inhibited in cells expressing
the Grb2/WA mutant compared with Grb2/WT-expressing
cells (Fig. 2B) (0.9  0.2 versus 4.5  0.9-fold, n  3, p  0.05).
Importantly, PDK1 association with SHPS-1 was also reduced
in response to IGF-I in cells expressing Grb2/WA (1.0  0.2-
versus 5.2  1.1-fold, n  3, p  0.01) (Fig. 2C). To control for
nonspecific conformational changes in Grb2, we measured
Pyk2-Grb2 association because this interaction occurs through
an SH2 domain in Grb2 binding to phosphotyrosine 881 in
Pyk2 (27, 34–37). The results showed that IGF-I-stimulated
Pyk2-Grb2 association was unchanged (supplemental Fig. 3).
SMCs expressing Grb2/WA mutant also showed decreased
AKT Thr308 phosphorylation in response to IGF-I (67  11%
reduction in PDK1/PAmutant cells, n  3, p  0.01) (Fig. 2D).
Because it was likely that the SH3 domain in Grb2 was bind-
ing to a proline-rich sequence in PDK1, a mutant in which
prolines 71 and 74 in PDK1 were substituted with alanine
(PDK1/PA)was constructed and expressed in vitro and in living
cells. In vitro binding assays clearly showed that wild-type
PDK1 (PDK1/WT) was able to directly bind to Grb2, whereas
the PDK1/PA mutant did not bind to Grb2 in vitro (Fig. 3A).
Following transfection, the levels of HA and PDK1 were con-
firmed to be the same when PDK1/WT and PDK1/PAmutant-
expressing cells were compared (supplemental Fig. 2B). The
cells expressing the PDK1/PAmutant had significantly reduced
PDK1-Grb2 association in response to IGF-I compared with
PDK1/WT-expressing cells (Fig. 3B) (1.1  0.1- versus 5.2 
0.8-fold, n  3, p  0.01). More importantly, substitution for
these prolines in PDK1 resulted in a major reduction in PDK1
recruitment to SHPS-1 comparedwith the PDK1/WT-express-
ing cells (1.3  0.4- versus 4.6  0.9-fold, n  3, p  0.05) (Fig.
3C). However, expression of this mutant did not alter Grb2
association with SHPS-1 (Fig. 3D). AKT Thr308 phosphoryla-
tion was also significantly decreased in cells expressing the
PDK1/PA mutant (63  9% reduction in PDK1/PA mutant
cells, n  3, p  0.05) (Fig. 3E). To determine whether Grb2-
mediated recruitment of PDK1 to SHPS-1 was specific for reg-
ulating IGF-I-stimulated AKT Thr308 phosphorylation, EGF
was used in a similar experiment. In contrast to IGF-I, expres-
sion of the PDK1/PA mutant did not alter EGF-stimulated
phosphorylation of AKT Thr308 (Fig. 3F).
Prior studies had shown that Pyk2 binding to Grb2 occurred
through Pyk2 phosphotyrosine 881 binding to a Grb2 SH2
domain (34–37), and we have shown that tyrosine phosphory-
lation of Pyk2 mediates Grb2 recruitment to the SHPS-1 signal-
ing complex (27). To confirm the importance of Grb2 associa-
tion with SHPS-1 for PDK1 recruitment and to control for
PDK1 overexpression, we utilized Pyk2/Y881F mutant-ex-
pressing cells that we had shown previously had attenuated
Grb2 association with SHPS-1 (27). Mutation of Pyk2/Y881F
significantly inhibited Pyk2-PDK1 association (1.0  0.1 versus
4.7  0.8-fold, n  3, p  0.01) and PDK1 recruitment to
SHPS-1 (1.1  0.1 versus 5.0  1.1-fold, n  3, p  0.01)
(supplemental Fig. 4A), leading to impaired AKT Thr308 phos-
phorylation (supplemental Fig. 4C).
IGF-I-stimulated PDK1 Recruitment to SHPS-1 Is Required
for AKT Thr308 Phosphorylation—To determine the functional
significance of loss of PDK1 recruitment to SHPS-1, thePKD1/PA
and Pyk2/Y881F mutants were utilized. The PDK1/PA mutant
cells had impaired phosphorylation of PDK1 on Tyr373/376 in
response to IGF-I compared with PDK1/WT cells (0.9  0.3
versus 3.6  0.5-fold, n  3, p  0.05) (Fig. 4A). Similarly, cells
expressing Pyk2/Y881F had impaired Tyr373/376 phosphoryla-
tion in response to IGF-I (1.1 0.1- versus 3.9 0.6-fold, n 3,
FIGURE 2. Grb2/WA mutant impairs PDK1 recruitment to SHPS-1 in
response to IGF-I. A, nontransfected, confluent cultures were serum-starved
overnight and then stimulated with IGF-I. Cell lysates were immunoprecipi-
tated (IP) with anti-PDK1 and immunoblotted (IB) for Grb2. To control the
loading, the blot was stripped and reprobed with anti-PDK1. B and C, quies-
cent HA-tagged Grb2/WT or HA-tagged Grb2/WA-expressing SMCs were
stimulated with IGF-I. Cell lysates were immunoprecipitated with anti-HA (B)
or PDK1 (C) and immunoblotted for the protein of interest. To control the
loading, the blots were stripped and reprobed with anti-HA (B) or anti-PDK1
antibodies (C). D, 20 l of cell lysate from the same experiment was used for
detection of phospho-AKT (Thr308). The blot was stripped and reprobed with
anti-AKT as a loading control.
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p 0.01) (supplemental Fig. 4B). To confirm the importance of
SHPS-1 localization for PDK1 activation, Tyr373/376 phos-
phorylation was determined following SHPS-1 immunopre-
cipitation. As shown in Fig. 4B, the PDK1 that was im-
munoprecipitated with SHPS-1 from cells expressing
PDK1/WT showed a major increase in Tyr373/376 phosphory-
lation, whereas the same immunoprecipitate from cells ex-
pressing the PDK1/PAmutant showed minimal tyrosine phos-
phorylation. More importantly, the mutation of PDK1/PA
inhibited the ability of IGF-I to enhance PDK1 kinase activity
compared with cells expressing PDK1/WT (1.38 0.16- versus
2.8  0.4-fold, n  5, p  0.05) (Fig. 4C).
AKT membrane localization (38) has been shown to be
essential for its activation, includingThr308 phosphorylation (1,
39). To exclude the possibility that decreased AKT Thr308
phosphorylation was due to altered AKT membrane localiza-
tion, AKT membrane recruitment in response to IGF-I stimu-
lation was analyzed. SMC expressing PDK1/PAmutant had the
same amount of AKT localized in the membrane fraction com-
pared with cells expressing PDK1/WT, whereas localization of
PDK1 in the membrane fraction was impaired in response to
IGF-I (1.4 0.3- versus 3.3 0.5-fold,n 3, p 0.05) (Fig. 5A).
Similarly, AKT Thr308 phosphorylation in the membrane frac-
tion was significantly decreased in cells expressing the
PDK1/PA mutant (74  12% reduction in PDK1/PA mutant
cells, n  3, p  0.05) (Fig. 5A). To exclude the possibility that
changes in PIP3 generation by PI3K accounted for the change in
PDK1 recruitment to SHPS-1 in response to IGF-I, SMCs were
exposed to IGF-I in the presence of a PI3K inhibitor, and SHPS-
1-PDK1 association was determined. Inhibition of PI3K had no
effect on PDK1-SHPS-1 association (Fig. 5B). Additionally,
there was a comparable increase in PI3K activity in cells
expressing the PDK1/PA mutant compared with cells express-
ing PDK1/WT (Fig. 5C). Similarly, whenwe quantified theAKT
Ser473 phosphorylation response in cells expressing this
mutant, there was no difference compared with SMCs express-
ing PDK1/WT (Fig. 5D).
Disruption of PDK1-mediated Signaling Increases Cell
Apoptosis—AKT enhances cell survival by phosphorylating
Thr32 in the forkhead transcription factor FOXO3a, which
leads to its nuclear exclusion (40). Members of the FOXO fam-
ily of transcription factors exert their apoptosis-inducing or cell
FIGURE 3. PDK1 polyproline motif provides a binding site for the Grb2
SH3 domain, which mediates IGF-I-induced PDK1 recruitment to SHPS-1.
A, PDK1 directly binds to Grb2 through a polyproline-SH3 domain interaction
in vitro. The interaction of [35S]methionine-labeled PDK1/WT or PDK1/PA
mutant with Grb2 was determined using in vitro binding assays as described
under “Experimental Procedures.” Images were obtained using a Storm 870
PhosphorImager. T, the expressed protein; W, the last wash; E, the eluate
(supernatant after elution from the Grb2 beads). B–D, quiescent HA-tagged
PDK1/WT or HA-tagged PDK1/PA-expressing SMCs were stimulated with
IGF-I. Cell lysates were immunoprecipitated (IP) with anti-HA (B and C) or
anti-Grb2 (D) and immunoblotted (IB) for the protein of interest. To control
the loading, the blots were stripped and reprobed with anti-HA (B and C) or
anti-Grb2 (D). The graphs show the mean result from three independent
experiments expressed as relative amount of Grb2 associated with PDK1/
total PDK1 that was immunoprecipitated or PDK1 associated with SHPS-1/
total PDK1 in response to IGF-I (B and C, bottom). **, p  0.01; *, p  0.05;
significant difference in two cell types. E, quiescent HA-tagged PDK1/WT- and
PDK1/PA-expressing SMCs were stimulated with IGF-I. The cell lysates were
directly immunoblotted for detection of phospho-AKT (Thr308). The blots
were stripped and reprobed with anti-AKT as a loading control. The graph
shows the mean result from three independent experiments expressed as
relative phospho-AKT/AKT ratio for phospho-Thr308 (bottom). *, p  0.05, sig-
nificant difference in two cell types. F, EGF-induced AKT Thr308 or Ser473 phos-
phorylation in the PDK1/PA mutant or PDK1/WT cells. Both PDK1/WT and
PDK1/PA cells were exposed to EGF (50 ng/ml, 5 min), and cell lysates were
analyzed by direct immunoblotting for phospho-AKT (Thr308 or Ser473). The
blots were stripped and reprobed with anti-AKT as a loading control. Error
bars represent S.E.
FIGURE 4. Impairment of Grb2-PDK1 association leads to reduced tyro-
sine phosphorylation and activation of PDK1 in response to IGF-I. A, qui-
escent HA-tagged PDK1/WT and PDK1/PA-expressing SMCs were stimulated
with IGF-I. The cell lysates were directly immunoblotted for phospho-PDK1
(Tyr373/376). The blot was stripped and reprobed with anti-PDK1 as a loading
control. B, confluent HA-tagged PDK1/WT and PDK1/PA cell cultures were
serum-starved overnight and treated with or without IGF-I for 5 min. Cell
lysates were immunoprecipitated (IP) with anti-SHPS-1 or control IgG and
immunoblotted (IB) for pPDK1 (Tyr373/376). To control the loading, the blot
was stripped and reprobed with anti-SHPS-1. The supernatants were immu-
noblotted for detection of phospho-PDK1 (Tyr373/376) (bottom). The blot was
stripped and reprobed with anti--actin as a loading control. C, confluent
HA-tagged PDK1/WT and PDK1/PA cell cultures were serum-starved over-
night and treated with IGF-I. Equivalent amounts of protein were immuno-
precipitated with anti-PDK1, and the immunoprecipitates were assayed for
PDK1 activity as described under “Experimental Procedures.” The values are
the mean  S.E. (error bars) from three independent experiments. *, p  0.05,
significant difference between the two cell types.
Role of PDK1 Recruitment to SHPS-1
29420 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 38 • SEPTEMBER 17, 2010
cycle-inhibitory functions by promoting the transcription of
various proteins, including p27Kip1 (p27) (41). In cells express-
ing the PDK1/PA mutant, phosphorylation of Thr32 in
FOXO3a was significantly decreased compared with PDK1/
WT-expressing cells in response to IGF-I (Fig. 6A) (1.0  0.1-
versus 2.5  0.3-fold, n  3, p  0.01). SMCs expressing
PDK1/PA had impaired IGF-I-dependent down-regulation of
p27 compared with SMC expressing PDK1/WT (Fig. 6B) (3 
2% versus 73 8% in IGF-I-dependent down-regulation of p27,
n  3, p  0.01). Because this signaling event is linked to apo-
ptosis, we investigated apoptotic cell death in SMC expressing
the mutant PDK1/PA following acute exposure to high glucose
(26, 42). Using this paradigm, cells expressing PDK1/WT had
an 87  14% reduction in the number of TUNEL-positive cells
in response to IGF-I, whereas IGF-I conferred no protection
from apoptotic cell death in the PDK1/PA mutant-expressing
cells (3.5% reduction in the number of TUNEL-positive cells)
(Fig. 6C). To further characterize cellular apoptosis, we mea-
sured cleaved caspase-3, which indicates caspase-3 activity in
this cell type. In the PDK1/WT cells, IGF-I was more effective
in preventing caspase-3 cleavage than in PDK1/PAmutant cells
(79.1% reduction versus 6.5% reduction, n  3, p  0.001) (Fig.
6D). In addition, PDK1/PA mutant-expressing cells had in-
creased basal cleaved caspase-3, which is consistent with
increased TUNEL-positive cells compared with PDK1/WT
(Fig. 6, C and D). These results indicate that impairment of
PDK1 recruitment to SHPS-1 in cells expressing PDK1/PA
mutant inhibits IGF-I-induced AKT activation, leading to an
increase in apoptotic cell death.
DISCUSSION
Previous studies have shown that in response to hyperglyce-
mic stress, SHPS-1 functions as a scaffold protein for IGF-I
signaling and that recruitment of signaling proteins to this scaf-
fold is required for IGF-I-stimulated PI3K and MAPK activa-
tion as well as cell migration and proliferation (23–25).
Recently, we reported that IGF-I stimulates the recruitment of
Pyk2 to the SHPS-1 signaling complex via its direct binding to
Src. Src then phosphorylates Pyk2 Tyr881, which creates a bind-
ing site for Grb2, resulting in recruitment of Grb2 to the
SHPS-1 complex (27). Grb2 also recruits the p85 subunit of
PI3K, leading to PI3K activation and enhanced AKT Ser473
phosphorylation (25). Although membrane recruitment of
PDK1 is known to be essential for AKTThr308 phosphorylation
(1, 32), the underlying mechanism that mediates PDK1 mem-
brane recruitment and the specific adaptor proteins that are
required have not been delineated. Recently, Nakamura et al.
(43) demonstrated that Freund-1/Akil, a cytoplasmic protein,
bound to PDK1 and, in conjunction with the epidermal growth
factor (EGF) receptor, modulated PDK1 translocation to the
plasmamembrane following EGF stimulation. This interaction
was required for EGF-stimulated PDK1 activation. In contrast,
they showed that IGF-I-stimulated PDK1 activation and AKT
Thr308 phosphorylation did not depend upon Fruend-1-PDK1
association (43). This finding led those authors to speculate that
other scaffold proteins might exist that mediated the effect of
IGF-I receptor activation of PDK1.
The results of this study provide evidence that SHPS-1 is an
important scaffold for assembly of a complex that includes
Pyk2-Grb2 and that Grb2 mediates PDK1 recruitment in
response to IGF-I. Assembly of this complex is required for
membrane localization and tyrosine phosphorylation of PDK1,
leading to its activation, which results in enhancement of AKT
Thr308 phosphorylation and cell survival.
In contrast to EGFR-Fruend1-PDK1 complex assembly, the
complex studied herein does not associate directly with IGF-I
receptor. Furthermore, unlike EGFR-Freund-1-PDK1, there is
no direct interaction between SHPS-1 and PDK1. SHP2, which
is the component of this complex that binds directly to SHPS-1,
recruits Src-Pyk2-Grb2, andGrb2 binds directly to PDK1. Con-
sistent with the IGF-I-regulated mechanism being distinct
from the EGF-mediated pathway is our observation that
EGF-stimulated AKT Thr308 phosphorylation was not
impaired in cells expressing the PDK1/PAmutant that could
not bind to Grb2. This supports the conclusion that EGF and
IGF-I are stimulating PDK1 membrane recruitment through
different signaling pathways that involve the assembly of dis-
tinct membrane-associated scaffolds, each containing
unique components.
Several proteins have been reported to interact with PDK1,
including HSP90, Grb14, mAKAP , and TUSC4. HSP90 and
TUSC4 have been reported to modulate PDK1 activity (10,
44–47). However, only Freund-1-EGFR and Grb14-IR have
been shown to recruit PDK1 to the cell membrane and thereby
facilitate its activation. In the present study, SHPS-1-Grb2-me-
diated membrane recruitment of PDK1 was dependent upon a
direct binding interaction between Grb2 and PDK1 (Fig. 5A).
FIGURE 5. Expression of the PDK1/PA mutant reduces PDK1 membrane
localization but not PI3K activity. A, membrane proteins were isolated as
described under “Experimental Procedures” and immunoblotted (IB) with
anti-PDK1, anti-AKT, or anti-phospho-AKT (Thr308). The blots were stripped
and reprobed with anti-caveolin as a membrane fraction marker and anti-14-
3-3 as a cytoplasmic fraction marker. B, confluent cultures were serum-
starved overnight and incubated with or without LY294002 (10 M) for 1 h.
IGF-I was added for 5 min. The cell lysates were immunoprecipitated (IP) with
anti-SHPS-1, followed by immunoblotting for PDK1. The blot was stripped
and reprobed with anti-SHPS-1 as a loading control. C, confluent HA-tagged
PDK1/WT and PDK1/PA cell cultures were serum-starved overnight and
treated with or without IGF-I for 5 min. The anti-p85 immunoprecipitates
were washed, and the pellets were incubated with PIP3 and [-
32P]ATP, as
described under “Experimental Procedures.” Radiolabeled PIP3 was sepa-
rated using thin layer chromatography. A representative autoradiogram is
shown. D, quiescent PDK1/WT- and PDK1/PA-expressing SMCs were stimu-
lated with IGF-I. The cell lysates were directly immunoblotted for detection of
phospho-AKT (Ser473). The blots were stripped and reprobed with anti-AKT as
a loading control.
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This occurred via the SH3 domain in Grb2 binding to a
polyproline sequence in PDK1. Grb2 is a versatile adapter pro-
tein that interacts with multiple signaling elements through its
SH2 and SH3 domains. In addition to adaptor protein-medi-
ated membrane localization of PDK1, it is well established that
phospholipid metabolites generated by PI3K modulate PDK1
membrane association and activation (48). However, in this
study, cells expressing the PDK1/PA mutant showed normal
PI3K activation and PIP3 production in response to IGF-I (Fig.
5C) but impaired PDK1membrane recruitment and activation.
Although previous studies have shown that PIP3 generation
plays an important role in pleckstrin homology domain-medi-
ated PDK1 localization to the membrane (32, 48, 49), our find-
ings suggest that the generation of PIP3 alone is not sufficient
for PDK1 membrane recruitment in response to IGF-I. This is
consistent with a prior study that showed that a pleckstrin
homology domain-deleted form of PDK1 underwent insulin-
dependent membrane association (10). Therefore, we propose
that PDK1 association with the
adaptor proteins, which can be
localized on membrane-associated
scaffolds, represents an important
mechanism for PDK1 recruitment.
Full activation of PDK1 requires
not only membrane recruitment
but also tyrosine phosphorylation.
Growth factor stimulation leads to
sequential phosphorylation of Tyr9
and Tyr373/376 (11, 14, 16, 17), and
substitutions for these phosphoty-
rosines result in decreased PDK1
activity (9, 13, 14, 16, 47). Previous
studies showed that Pyk2 activates
PDK1, but the mechanism was not
determined (9, 12, 18). Our recent
study showed that IGF-I stimulates
Pyk2 Tyr881 phosphorylation, and
expression of Pyk2/Y881F that had
impairedGrb2 binding led to failure
to recruit PDK1 to SHPS-1 (sup-
plemental Fig. 4A) (27). Conversely,
overexpression of Pyk2 resulted in
an increased phosphorylation of
PDK1 at Tyr373/376 in response to
IGF-I (supplemental Fig. 4B). We
propose that this allows Src to be in
close proximity to PDK1, resulting
in enhanced Src-dependent PDK1
Tyr373/376 tyrosine phosphoryla-
tion. That this interaction occurred
when both proteins were associated
with SHPS-1 is suggested by our
observation that, following SHPS-1
pull-down, the immunoprecipitate
contained almost all of the tyrosine-
phosphorylated PDK1 (Fig. 4B).
Prior studies have reported that
IGF-I enhances PDK1 activity and
increases cell survival (17, 50). Our studies show that when
SMCs are exposed to hyperglycemic stress, they undergo
apoptosis unless they are exposed to IGF-I (42) and that
assembly of the signaling complex on SHPS-1 is required to
prevent apoptosis (26). Because inhibition of PDK1 recruit-
ment to SHPS-1 impaired IGF-I-dependent cell survival, we
conclude that PDK1 recruitment to SHPS-1 scaffold is an
integral component of the process by which IGF-I inhibits
hyperglycemic stress-induced apoptosis. We noted a 2-fold
difference in basal apoptotic cell death between PDK1/WT
and PDK1/PA mutant-overexpressing cells. We postulate
that a difference in wild-type PDK1 could account for this
trend. The increased amount of PDK1 in PDK1/WT-overex-
pressing cells may amplify the effect of growth factors on cell
survival. In contrast, cells overexpressing the PDK1/PA
mutant may have suppressed the endogenous PDK1, which
would amplify hyperglycemia-induced cell apoptosis. To
support this conclusion, we also detected a difference in the
FIGURE 6. Grb2-PDK1 association regulates AKT-dependent FOXO3a phosphorylation, p27 protein
expression, and cell survival in response to IGF-I. A, quiescent PDK1/WT- and PDK1/PA-expressing SMCs
were stimulated with IGF-I for 5 min. The cell lysates were directly immunoblotted (IB) for phospho-FOXO3a
(Thr32). The blot was stripped and reprobed with anti-FOXO3a as a loading control. B, quiescent PDK1/WT- and
PDK1/PA-expressing SMCs were treated with or without IGF-I overnight. The cell lysates were directly immu-
noblotted for p27. The blot was stripped and reprobed with anti--actin as a loading control. C and D, apopto-
tic cell death and caspase-3 activity are attenuated by IGF-I treatment, which requires PDK1 activation. The
TUNEL assay was conducted as described under “Experimental Procedures.” SMCs expressing PDK1/WT or
PDK1/PA were grown to 80% confluence in normal glucose (5 mM) with 10% FBS in 6-well culture plates and
then starved overnight in serum-free DMEM-H containing 25 mM glucose. 48 h after the addition of IGF-I, the
apoptotic cell number was determined by counting apoptotic nuclei using fluorescence microscopy (C, top,
photomicrograph; bottom, quantitation of apoptotic cells). ***, p  0.001, a significant difference between two
different treatments. Additional cultures were lysed and analyzed by immunoblotting using anti-cleaved
caspase-3 (cleaved CASP3) (D). The blots were stripped and reprobed with anti--actin as a loading control. The
protein levels were quantified using scanning densitometry. The graph shows the mean result from three
independent experiments expressed as the cleaved CASP3/-actin ratio (D, bottom). ***, p  0.001, a signifi-
cant difference between two different treatments; NS, not significant. Error bars represent S.E.
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basal level of FOXO3a phosphorylation, p27 expression, and
cleaved caspase-3.
PDK1-mediated phosphorylation of AKTThr308 activates its
downstream signaling events that mediate PDK1-dependent
cell survival (43, 50, 51). Recent studies have emphasized the
importance of AKT Thr308 phosphorylation for downstream
signaling and growth factor-stimulated biologic actions. Ito et
al. (52) showed that selective loss of PDK1-mediated Thr308
phosphorylation in mice with retention of Ser473 phosphory-
lation resulted in deficient FOXO3a nuclear transport and
increased cardiomyocyte apoptosis. Similarly, Padmanabhan
et al. (53) showed that selective inhibition of AKT Thr308
dephosphorylation resulted in FOXO3a nuclear exclusion and
decreased FOXO3a augmented gene expression in response to
insulin. Other studies have shown that full activation of AKT
Thr308 phosphorylation is required for phosphorylation of
GSK3 and FOXO3a (51, 54, 55), which are required to inhibit
apoptosis. Taken together, these results support the conclusion
that selective activation of AKT Thr308 by PDK1 is an impor-
tant component of IGF-I receptor-linked signaling events that
stimulate FOXO3a nuclear exclusion, thus leading to down-
regulation of p27 and inhibition of apoptosis.
Our prior studies have demonstrated that AKT is also
recruited to SHPS-1 (26). Therefore, it is possible that the
decrease in AKT Thr308 phosphorylation is due to a reduction
in AKT recruitment to SHPS-1. However, our results show that
in cells expressing the PDK1/PA mutant, AKT Ser473 phosphor-
ylation and PIP3 generation in response to IGF-I stimulation
are intact, and AKT recruitment to SHPS-1 is not attenuated
(Fig. 5A). Therefore, AKT is appropriately recruited to the cell
membrane, and this does not account for reduced AKT Thr308
phosphorylation. This highlights
the importance of PDK1 recruit-
ment to SHPS-1 for AKT Thr308
phosphorylation in response to
IGF-I.
Based on these findings, we pro-
pose a model of PDK1 membrane
recruitment and AKT Thr308 phos-
phorylation in response to IGF-I
(Fig. 7). Following SHPS-1 tyrosine
phosphorylation, SHP2-Src-Pyk2
is recruited to SHPS-1 complex,
resulting in Pyk2 Tyr881 phosphor-
ylation, which creates a binding
site for Grb2 (27). Grb2 recruits
PDK1 to the membrane via an SH3
domain-polyproline interaction,
resulting in enhanced Src-Pyk2-de-
pendent tyrosine phosphorylation
of PDK1 and its optimal enzymatic
activation. This leads to enhanced
AKT Thr308 phosphorylation and
cell survival in response to IGF-I.
The localized interaction of these
key signaling molecules on SHPS-1
may thus represent a novel pathway
that plays a critical role in prevent-
ing hyperglycemic stress-induced apoptosis and potentially
leads to enhanced SMC proliferation.
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